Patrick Campbell

FDA approvals broaden ALYFTREK and TRIKAFTA eligibility to nearly 95% of US cystic fibrosis patients using a functional, mechanism-based variant criterion.

Indirect data suggest oral semaglutide may reduce weight more than orforglipron, but cross-trial comparisons limit clinical interpretation.

FDA fully approves sparsentan for FSGS in kids 8+, offering first targeted option and stronger proteinuria drops than irbesartan.

The FDA has accepted LEO Pharma's sNDA for delgocitinib cream for moderate-to-severe chronic hand eczema in adolescents.

Older adults with both anemia and elevated neurofilament light chain levels faced a more than 3.5-fold increased risk of developing dementia.

The FDA accepted Genentech's sBLA for obinutuzumab in SLE based on positive phase 3 ALLEGORY trial results, with a decision expected by December 2026.

The FDA approved a lumateperone sNDA adding relapse prevention data in schizophrenia based on a 63% reduction in relapse risk versus placebo.

Details on 11 key abstracts with clinical relevance for primary care, from menopause management to cervical cancer screening.

Per CNN, Alito’s order is in effect until May 11, with responses to the case requested by Thursday, May 7.

Until this decision, clinicians relied on off-label, interferon-based regimens with limited efficacy.